Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009
Oncoscience | October 9th, 2009
On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented. At ...
Oncoscience | October 4th, 2008
Oncoscience AG is a member of the German Funcrypta project. Within the scope of this cooperation a poster will be presen...
Oncoscience AG receives EU orphan drug status for the EGFR monoclonal antibody Nimotuzumab (Theraloc®) for the treatment of pancreatic cancer.
Oncoscience | April 22nd, 2008
Oncoscience AG announced that their anti-cancer drug Nimotuzumab (Theraloc®) has been designated an orphan drug by the ...
The European Medicines Agency, EMEA, concludes its formal validation of the marketing authorization application for Theraloc® (Nimotuzumab) positively
Oncoscience | October 26th, 2007
The application for marketing authorization of Theraloc® (Nimotuzumab) was submitted to EMEA on October 4th, 2007. Aft...
Oncoscience | October 13th, 2007
On October 12th, 2007 Theraloc® was approved in the Ukraine by the Ministry of Health of Ukraine. As of now Theraloc®...